© Valo Therapeutics

New CEO for Valo Therapeutics

Valo Therapeutics Limited, a cancer immunotherapy company developing neoantigen-coated oncolytic viruses as therapeutic vaccines has appointed Michael Stein to Chief Executive Officer. Stein already served as part-time co-Chairman since the company’s inception in 2017.

Stein’s career includes executive leadership and board roles with numerous University start-ups, most recently breaking the UK record for a seed round as CEO of OxStem, a biotechnology company focused on regenerative medicine which was spun-out of the University of Oxford in 2016. Another notable success includes the Map of Medicine which Dr Stein co-founded with UCL in 2001, taking it from start-up to a multi-million-pound exit to Informa plc in 2005 before it was sold to Hearst Inc. in 2008, where he continued to serve as EVP (Healthcare Innovation) until 2011.

Prior to his business career, Stein enjoyed a highly relevant academic career which included the first description of the alternative pathway of immunologic macrophage activation which became known as the M2 Macrophage phenotype (Stein et al, J Exp Med 1992). Stein was awarded a Junior Research Fellowship in Medicine from Trinity College, Oxford, having received a DPhil (PhD) in Physiological Sciences (Immunology) from the University of Oxford as a Rhodes Scholar. In addition, Dr Stein received a MB ChB (MD) (Hons) and a BSc in Biochemistry (First Class Honours) from the University of Cape Town.

Valo Therapeutics was founded in January 2017 and is headquartered in Oxford, UK.